Table of Contents

Research Articles

• Research Articles | AuthorChoice

  Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

  Sumanta K. Pal, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, Raanan Berger, David I. Quinn, Matthew D. Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean-Pierre Delord, Jan H.M. Schellens, Gwenaelle Gravis, Jacques Medioni, Pablo Maroto, Virote Sriuranpong, Chaiyut Charoentum, Howard A. Burris, Viktor Grünwald, Daniel Petrylak, Ulka Vaishampayan, Eliahu Gez, Ugo De Giorgi, Jae-Lyun Lee, Jens Voortman, Sumati Gupta, Sunil Sharma, Amir Mortazavi, David J. Vaughn, Randi Isaacs, Katie Parker, Xueying Chen, Kun Yu, Dale Porter, Diana Graus Porta and Dean F. Bajorin

  Cancer Discov July 1 2018 8 (7) 812-821; DOI:10.1158/2159-8290.CD-18-0229

  
  

  The FGFR1–3 inhibitor BGJ398 achieved responses with an acceptable safety profile in an expansion cohort of 67 patients with metastatic FGFR3-altered urothelial carcinoma.

• Research Articles | AuthorChoice

  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

  Ferdinandos Skoulidis, Michael E. Goldberg, Danielle M. Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Peter M. Szabo, Han Chang, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph Szustakowski, Patrik Vitazka, Robin Edwards, Jose A. Bufill, Neelesh Sharma, Sai-Hong I. Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jimenez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh F. Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galan-Cobo, Haifa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez-Canales, Pamela A. Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino-Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok-Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker and John V. Heymach

  Cancer Discov July 1 2018 8 (7) 822-835; DOI:10.1158/2159-8290.CD-18-0099

  
  

  In patients with KRAS-mutant lung adenocarcinoma, co-occurring alterations in STK11 conferred primary resistance to PD-1 blockade, suggesting that genomic profiling may guide selection of patients likely to respond.

• Research Articles | AuthorChoice

  Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

  Vivek Subbiah, Justin F. Gainor, Rami Rahal, Jason D. Brubaker, Joseph L. Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P. Sheets, Douglas Wilson, Kevin J. Wilson, Lucian DiPietro, Paul Fleming, Michael Palmer, Mimi I. Hu, Lori Wirth, Marcia S. Brose, Sai-Hong Ignatius Ou, Matthew Taylor, Elena Garralda, Stephen Miller, Beni Wolf, Christoph Lengauer, Timothy Guzi and Erica K. Evans

  Cancer Discov July 1 2018 8 (7) 836-849; DOI:10.1158/2159-8290.CD-18-0338

  
  

  BLU-667 is a potent selective RET inhibitor with activity against multiple RET mutations and fusions, and it achieved clinical responses with limited toxicity in four patients with RET-driven tumors.

• Research Articles | AuthorChoice

  NF-κB–Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis

  Paulo Rodrigues, Saroor A. Patel, Louise Harewood, Ioana Olan, Erika Vojtasova, Saiful E. Syafruddin, M. Nazhif Zaini, Emma K. Richardson, Johanna Burge, Anne Y. Warren, Grant D. Stewart, Kourosh Saeb-Parsy, Shamith A. Samarajiwa and Sakari Vanharanta

  Cancer Discov July 1 2018 8 (7) 850-865; DOI:10.1158/2159-8290.CD-17-1211

  
  

  High-throughput enhancer profiling identifies metastasis-associated enhancers that are activated to drive CXCR4 expression and metastatic colonization in clear cell renal cell carcinoma.

• Research Articles

  PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells

  Seong M. Kim, Tricia T. Nguyen, Archna Ravi, Peter Kubiniok, Brendan T. Finicle, Vaishali Jayashankar, Leonel Malacrida, Jue Hou, Jane Robertson, Dong Gao, Jonathan Chernoff, Michelle A. Digman, Eric O. Potma, Bruce J. Tromberg, Pierre Thibault and Aimee L. Edinger

  Cancer Discov July 1 2018 8 (7) 866-883; DOI:10.1158/2159-8290.CD-17-1215

  
  

  AMPK-dependent macropinocytosis of necrotic cell debris enhances the growth and survival of PTEN-deficient prostate cancer cells.

• Research Articles

  CDK6 Antagonizes p53-Induced Responses during Tumorigenesis

  Florian Bellutti, Anca-Sarmiza Tigan, Sofie Nebenfuehr, Marlies Dolezal, Markus Zojer, Reinhard Grausenburger, Svenja Hartenberger, Sebastian Kollmann, Eszter Doma, Michaela Prchal-Murphy, Iris Z. Uras, Alexander Höllein, Donna S. Neuberg, Benjamin L. Ebert, Anna Ringler, Andre C. Mueller, Joanna I. Loizou, Philip W. Hinds, Claus Vogl, Gerwin Heller, Stefan Kubicek, Johannes Zuber, Marcos Malumbres, Matthias Farlik, Andreas Villunger, Karoline Kollmann and Veronika Sexl

  Cancer Discov July 1 2018 8 (7) 884-897; DOI:10.1158/2159-8290.CD-17-0912

  
  

  CDK6 antagonizes p53 to promote leukemia cell growth, and CDK6 loss promotes the outgrowth of p53 mutant malignant cell lines, suggesting a potential risk in therapeutic targeting of CDK6.